U.S. CLINICAL TRIAL OF ACELLULAR PERTUSSIS VACCINE

这项临床试验将比较三批无细胞百日咳疫苗， 彼此的疫苗。 此外，试验的第四个分支将 使用现有的全细胞疫苗。 试验的所有四个方面都将 使用百日咳疫苗结合白喉和破伤风。 的 承包商将招募约2000名受试者， 分配到试验的四个组中的一个。 免疫接种将 分别在两个月、四个月和六个月时给药。 将监测反应 通过在每次给药后24、72和168小时进行的随访电话， 次免疫 这些数据将与其他数据一起进行分析。 合作者来确定安全性。

This clinical trial will compare three lots of acellular pertussis vaccine with each other. In addition, a fourth arm of the trial will utilize the current whole cell vaccine. All four arms of the trial will utilize a pertussis vaccine combined with diphtheria and tetanus. The Contractor will recruit approximately 2000 subjects who will be randomly assigned to one of the four arms of the trial. Immunizations will be administered at two, four and six months. Reactions will be monitored by follow-up phone calls made at 24, 72 and 168 hours after each immunization. The data will be analyzed in conjunction with the other collaborators to determine the safety.